ArticleNarra J2026
Correlation between serum bone remodeling biomarkers and CTX-1 levels among patients with rheumatoid arthritis: A cross-sectional study at a provincial referral hospital in Indonesia.
Article in Narra J, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is associated with accelerated bone loss, partly mediated by dysregulation of the receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway, which regulates osteoclast activity. Carboxy-terminal cross-linked telopeptide of type I collagen (CTX-1) is a biochemical marker of bone resorption and may reflect increased skeletal turnover in RA. Although previous studies have evaluated RANKL, OPG, and the RANKL/OPG ratio in relation to bone mineral density, osteoporosis, and fracture risk, the correlations of circulating RANK, RANKL, and OPG with CTX-1 remain insufficiently characterized in patients with RA. The aim of this study was to evaluate the correlations of serum RANK, RANKL, and OPG levels with serum CTX-1 levels in patients with RA. An analytical cross-sectional study was conducted at a provincial referral hospital in Padang, Indonesia, from July to December 2024, during which patients with RA were recruited through consecutive sampling. Serum RANK, RANKL, OPG, and CTX-1 concentrations were measured using enzyme-linked immunosorbent assays. Correlations were assessed using Pearson's correlation analysis. The mean age of the patients was 40.30±5.08 years. The mean serum concentrations of RANK, RANKL, OPG, and CTX-1 were 5.20±2.83, 6.55±3.14, 0.17±0.09, and 2.10±1.10 ng/mL, respectively. Serum RANK and RANKL levels showed very strong positive correlations with CTX-1 levels (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.